CVRx, Inc.
Financials
Valuation Metrics
CVRx, Inc.'s Market Cap is $80M. At end of 2025 it was $186M. Ranked #3090 of 3,121 in US market (top 99%), #1435 of 1,463 on NASDAQ (top 98%), #201 of 205 in Health Care Equipment & Services (top 98%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $80M | US#3,090/3,121 Sec#201/205 |
| Revenue | $61M | US#2,758/3,121 Sec#193/205 |
| Net Income | $-52M | US—/3,121 Sec—/205 |
| Total Assets | $92M | US#3,067/3,121 Sec#202/205 |
| Net Assets | $20M | US#2,899/3,121 Sec#189/205 |
| Employees | 223 | US#2,480/3,121 Sec#170/205 |
| Value | ||
| P/B | 3.99x | US#2,016/3,121 Sec#116/205 |
| P/S | 1.30x | US#902/3,121 Sec#63/205 |
| FCF Yield | -51.57% | US—/3,121 Sec—/205 |
| Profitability | ||
| ROA | -56.31% | US#3,009/3,121 Sec#200/205 |
| Op. Margin | -79.49% | US#2,716/3,121 Sec#191/205 |
| Revenue Growth | 11.96% | US#1,108/3,121 Sec#74/205 |
| Financial Health | ||
| Debt Ratio | 362.50% | US#2,234/3,121 Sec#173/205 |
| Total Debt | $59M | US#2,576/3,121 Sec#152/205 |
| FCF | $-41M | US#2,505/3,121 Sec#174/205 |
| Cash | $65M | US#2,464/3,121 Sec#152/205 |
| Current Ratio | 8.04x | US#317/3,121 Sec#21/205 |
| Performance | ||
| 1Y Return | -55.75% | US#2,978/3,121 Sec#191/205 |
| 1M Return | 9.09% | US#273/3,121 Sec#37/205 |
| From 52W High | -73.45% | US#3,044/3,121 Sec#199/205 |
| 1Y MDD | -78.08% | US#3,051/3,121 Sec#196/205 |
| Trading | ||
| Volume | 296,449 shares | US#2,410/3,121 Sec#169/205 |
| Trading Value | $898240.00 | US#3,021/3,121 Sec#194/205 |
| Per Share | ||
| EPS | $-1.96 | US—/3,121 Sec—/205 |
| BPS | $0.75 | US#2,727/3,121 Sec#183/205 |
Company Info
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.